- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04198766
국소 진행성 또는 전이성 고형 종양(6가 OX40 작용제)이 있는 피험자에서 Pembrolizumab과 병용한 INBRX-106 및 INBRX-106에 대한 연구
국소 진행성 또는 전이성 고형 종양이 있는 피험자에서 Pembrolizumab과 병용한 INBRX-106 및 INBRX-106의 오픈 라벨, 다기관, 인간 최초, 용량 증량, 1상 연구
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Study Director - Inhibrx Biosciences, Inc
- 전화번호: 858-500-7833
- 이메일: clinicaltrials@inhibrx.com
연구 장소
-
-
-
Changhua, 대만
- 모집하지 않고 적극적으로
- Changhua Christian Hospital (CCH)
-
Kaohsiung City, 대만
- 모집하지 않고 적극적으로
- E-Da Cancer Hospital
-
Kaohsiung City, 대만
- 모집하지 않고 적극적으로
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Tainan, 대만
- 모집하지 않고 적극적으로
- National Cheng Kung University Hospital
-
Taipei, 대만
- 완전한
- Taipei Veterans General Hospital
-
-
-
-
-
Busan, 대한민국
- 아직 모집하지 않음
- Inje University College of Medicine
-
수석 연구원:
- IL-Hwan Kim, MD, PhD
-
Cheongju-si, 대한민국
- 아직 모집하지 않음
- Chungbuk National University Hospital
-
수석 연구원:
- Ki-Hyeong Lee, MD
-
Gyeonggi-do, 대한민국
- 모병
- The Catholic University of Korea, St. Vincent's Hospital
-
수석 연구원:
- Byoung Yong Shim
-
Hwasun, 대한민국
- 아직 모집하지 않음
- Chonnam National University Hwasun Hospital
-
수석 연구원:
- In-Jae Oh, MD, MS, PhD
-
Incheon, 대한민국
- 아직 모집하지 않음
- Gachon University Gil Medical Center
-
수석 연구원:
- Eun Kyung Cho, PhD, M.S
-
Seongnam-si, 대한민국
- 아직 모집하지 않음
- CHA Bundang Medical Center
-
수석 연구원:
- Yoon Beom Sang
-
Seoul, 대한민국
- 모병
- Asan Medical Center
-
연락하다:
- Bokyeong Jung, RN
- 이메일: bokyeong_jung@amc.seoul.kr
-
수석 연구원:
- Dae Ho Lee, MD
-
Seoul, 대한민국
- 모병
- Severance Hospital, Yonsei University Health System
-
연락하다:
- Miyeon Lee
- 이메일: lee_my@yuhs.ac
-
수석 연구원:
- Sun Mun Lim
-
Seoul, 대한민국
- 모병
- The Catholic University of Korea Seoul St. Mary's Hospital,
-
수석 연구원:
- SookHee Hong
-
연락하다:
- Na Ayn
- 이메일: Ahnna331@gmail.com
-
Seoul, 대한민국
- 아직 모집하지 않음
- Korea University Anam Hospital
-
수석 연구원:
- Yoon Ji Choi, MD, MS, PhD
-
Seoul, 대한민국
- 아직 모집하지 않음
- Hanyang University Seoul Hospital
-
수석 연구원:
- Myung- Ju Ahn, MD, PhD, MS
-
Seoul, 대한민국
- 아직 모집하지 않음
- Korea University Guro Hospital
-
수석 연구원:
- Sung Yong Lee
-
수석 연구원:
- Sung Yong Lee, MD, MS, PhD
-
Suwon, 대한민국
- 아직 모집하지 않음
- Ajou University Hospital
-
수석 연구원:
- Yong-Won Choi, MD
-
-
-
-
California
-
Duarte, California, 미국, 91010
- 모집하지 않고 적극적으로
- City of Hope
-
Glendale, California, 미국, 91204
- 모병
- Oncura Health
-
연락하다:
- Elizabeth Brown
- 이메일: Elizabeth.Brown@lahomg.com
-
수석 연구원:
- Sungwon Kyung, MD
-
La Jolla, California, 미국, 92037
- 아직 모집하지 않음
- UC San Diego Health - Moores Cancer Center
-
수석 연구원:
- Lyudmila Bazhenova, MD
-
Los Angeles, California, 미국, 90027
- 모병
- California Research Institute
-
수석 연구원:
- Ghassan Al-Jazayrly, MD
-
연락하다:
- Swati Shrestha
- 이메일: sw@caresinst.com
-
Los Angeles, California, 미국, 90069
- 모병
- Valkyrie Clinical Trials
-
수석 연구원:
- David Berz, MD
-
연락하다:
- Myo Zaw
- 이메일: myo.zaw@valkyrieclinicaltrials.com
-
Los Angeles, California, 미국, 90033
- 아직 모집하지 않음
- University of Southern California Norris Comprehensive Cancer Center
-
수석 연구원:
- Jorge Nieva, MD
-
Murrieta, California, 미국, 92562
- 모병
- Valkyrie Clinical Trials
-
수석 연구원:
- David Berz, MD
-
연락하다:
- Isabella Gudino
- 이메일: Isabella.gudino@vctcare.com
-
Santa Rosa, California, 미국, 95403
- 모병
- Providence Medical Foundation
-
수석 연구원:
- Ian Anderson, MD
-
연락하다:
- Clinical Research Coordinator
- 전화번호: 1181 707-521-3810
- 이메일: jackson.barnard@providence.org
-
-
Colorado
-
Lakewood, Colorado, 미국, 80228
- 아직 모집하지 않음
- Valkyrie Clinical Trials - Colorado
-
수석 연구원:
- Jason Henry, MD
-
-
Florida
-
Clermont, Florida, 미국, 34711
- 모병
- Clermont Oncology Center
-
수석 연구원:
- Gopal Kunta, MD
-
연락하다:
- Kiran Penta
- 이메일: kiran@aorcorp.com
-
Orange City, Florida, 미국, 32763
- 모병
- Mid Florida Hematology and Oncology Center
-
수석 연구원:
- Santosh Nair, MD
-
연락하다:
- Kiran Penta
- 이메일: kiran@aorcorp.com
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모집하지 않고 적극적으로
- Winship Cancer Institute - Emory University
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- 아직 모집하지 않음
- University of Illinois Cancer Center
-
수석 연구원:
- Frank Weinberg, MD, PhD
-
Chicago, Illinois, 미국, 60637
- 모집하지 않고 적극적으로
- The University of Chicago Medical Center
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- 모병
- University of Iowa
-
수석 연구원:
- Douglas Laux, MD
-
연락하다:
- Jordan Harrelson
- 전화번호: 319-467-5831
- 이메일: Jordan-harrelson@uiowa.edu
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40202
- 모병
- Norton Cancer Institute
-
수석 연구원:
- John Hamm, MD
-
연락하다:
- Jenn Broadway, RN
- 전화번호: 19535 502-629-2500
- 이메일: Jennifer.Broadway@nortonhealthcare.org
-
-
Michigan
-
Detroit, Michigan, 미국, 48202
- 모병
- Henry Ford Cancer Institute
-
수석 연구원:
- Amy Weise, MD
-
연락하다:
- Mahmoud Hossami
- 전화번호: 313-725-7842
- 이메일: mhossam1@hfhs.org
-
Detroit, Michigan, 미국, 48201
- 완전한
- Barbara Ann Karmanos Cancer Institute
-
Grand Rapids, Michigan, 미국, 49546
- 모집하지 않고 적극적으로
- START Midwest
-
-
Minnesota
-
Saint Louis Park, Minnesota, 미국, 55426
- 모집하지 않고 적극적으로
- HealthPartners Cancer Research Center
-
Saint Paul, Minnesota, 미국, 55101
- 완전한
- HealthPartners Cancer Research Center (Regions Hospital)
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- 아직 모집하지 않음
- Washington University in St. Louis School of Medicine
-
수석 연구원:
- Brett Herzog, MD, PhD
-
-
Montana
-
Billings, Montana, 미국, 59102
- 완전한
- Intermountain Health Cancer Centers of Montana
-
-
Nebraska
-
Grand Island, Nebraska, 미국, 68803
- 아직 모집하지 않음
- Nebraska Cancer Specialists - Grand Island
-
수석 연구원:
- Ralph Hauke, MD
-
Omaha, Nebraska, 미국, 68130
- 모병
- Nebraska Cancer Specialists
-
수석 연구원:
- Ralph Hauke, MD
-
연락하다:
- Lindsey Becker
- 전화번호: 402-691-5255
- 이메일: lbecker@nebraskacancer.com
-
-
New Jersey
-
Camden, New Jersey, 미국, 08103
- 아직 모집하지 않음
- MD Anderson Cancer Center at Cooper
-
수석 연구원:
- Polina Khrizman, MD
-
-
New York
-
The Bronx, New York, 미국, 10467
- 모집하지 않고 적극적으로
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- 모집하지 않고 적극적으로
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, 미국, 97213
- 모집하지 않고 적극적으로
- Providence Portland Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, 미국, 18103
- 아직 모집하지 않음
- Lehigh Valley Health Network
-
수석 연구원:
- Muhammad Rizvi, MD
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37923
- 아직 모집하지 않음
- University of Tennessee Health Science Center
-
수석 연구원:
- Sean Jordan, MD
-
Nashville, Tennessee, 미국, 37204
- 모집하지 않고 적극적으로
- Vanderbilt University School of Medicine
-
-
Texas
-
Dallas, Texas, 미국, 75230
- 완전한
- Sarah Cannon Research Institute at Mary Crowley
-
El Paso, Texas, 미국, 79915
- 완전한
- Renovatio Clinical - El Paso
-
San Antonio, Texas, 미국, 78229
- 완전한
- NEXT Oncology
-
The Woodlands, Texas, 미국, 77380
- 완전한
- Renovatio Clinical
-
Tyler, Texas, 미국, 75701
- 모병
- The University of Texas Health Science Center at Tyler
-
연락하다:
- Chaney Story
- 이메일: Chaney.Story@uttyler.edu
-
수석 연구원:
- Erminia Massarelli, MD, PhD, MS
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 완전한
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- 모병
- Froedtert Hospital and the Medical College of Wisconsin
-
수석 연구원:
- Jonathan Thompson, MD
-
연락하다:
- Ellen Smith
- 이메일: eksmith@mcw.edu
-
-
-
-
-
Singapore, 싱가포르
- 완전한
- Curie Oncology
-
Singapore, 싱가포르
- 완전한
- Icon Cancer Centre Farrer Park
-
Singapore, 싱가포르
- 완전한
- Icon Cancer Centre Mount Alvernia
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Select Inclusion Criteria:
- Males or females aged ≥18 years.
- Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
- Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
- Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
- For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
- For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
- For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
- All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
- PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
- Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.
Select Exclusion Criteria:
- Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
- Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
- Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- Additional in- and exclusion criteria per protocol.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1 INBRX-106 Escalation (Not Recruiting)
INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
실험적: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)
INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
|
|
실험적: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
|
|
실험적: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)
Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
|
|
실험적: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
다른 이름들:
|
|
실험적: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
다른 이름들:
|
|
활성 비교기: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
실험적: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
실험적: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
|
|
실험적: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting
Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
|
|
실험적: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)
Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
다른 이름들:
|
|
실험적: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
다른 이름들:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 |
|
실험적: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4 |
|
실험적: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
|
|
실험적: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC
Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
다른 이름들:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
다른 이름들:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4 |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
기간: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
기간: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
기간: ~2 years
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab |
~2 years
|
|
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
기간: ~2 years
|
The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1 |
~2 years
|
|
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
기간: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
기간: ~2 years
|
Major pathological response (mPR) and pathological complete response (cPR) criteria. |
~2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Area under the serum concentration time curve (AUC) of INBRX-106
기간: ~2 years
|
Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Maximum observed serum concentration (Cmax) of INBRX-106
기간: ~2 years
|
Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Trough observed serum concentration (Ctrough) of INBRX-106
기간: ~2 years
|
Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Time to Cmax (Tmax) of INBRX-106
기간: ~2 years
|
Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Immunogenicity of INBRX-106
기간: ~2 years
|
Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
기간: ~2 years
|
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
~2 years
|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
기간: ~2 years
|
Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
~2 years
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Clinical Lead, Inhibrx Biosciences, Inc
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 구강 질환
- 악구강 질환
- 비뇨생식기 신생물
- 남성 비뇨 생식기 질환
- 신장 질환
- 비뇨기과 질환
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 호흡기 질환
- 위장관 신생물
- 소화계 신생물
- 소화기계 질환
- 위장병
- 위장병
- 폐 질환
- 선암종
- 호흡기 신생물
- 흉부 신생물
- 피부병
- 비뇨기과 신생물
- 이비인후과 질환
- 신경외배엽 종양
- 신생물, 생식 세포 및 배아
- 신생물, 신경 조직
- 신장 신생물
- 기관지 암종
- 기관지 신생물
- 신경내분비종양
- 인두 신생물
- 이비인후과 신생물
- 인두 질환
- 모반과 흑색종
- 피부 신생물
- 피부 및 결합 조직 질환
- 두경부의 편평 세포 암종
- 신생물
- 위 신생물
- 암종
- 폐 신생물
- 암종, 편평 세포
- 암종, 신장 세포
- 암종, 비소세포폐
- 두경부 신생물
- 흑색종
- 조직학적 유형에 따른 신생물
- 신생물, 선상 및 상피
- 신생물, 편평 세포
- 구강 신생물
- 암종, 과도기 세포
- 구인두 신생물
- 부위별 신생물
- 하인두 신생물
- 아미노산, 펩티드 및 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 무기 화학 물질
- 염소 화합물
- 질소 화합물
- 구아닌
- Hypoxanthines
- 푸리 논
- 퓨린
- 글루타메이트
- 아미노산, 산성
- 아미노산
- 아미노산, 디카 르 복실
- 박습니다
- 사이클로 데카네
- Diterpenes
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 건강 관리 경제 및 조직
- 백금 화합물
- 경제학
- 페메트렉시드
- 젬시타빈
- 파클리탁셀
- 시스플라틴
- 펨브 롤리 주맙
- 구실
기타 연구 ID 번호
- Ph 1 Ph 2 INBRX-106
- KEYNOTE A99 and MK-3475-A99 (기타 식별자: Merck Sharp & Dohme LLC)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .